(GRCL) – Globe Newswire
-
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting &
-
Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
-
Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
-
Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
-
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
-
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
-
Gracell Biotechnologies to Participate in Jefferies Healthcare Conference
-
Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd
-
Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update
-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
-
Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023
-
Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023
-
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022
-
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2022
-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
-
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
-
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
-
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
-
Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies to Participate in Three Investor Conferences in May
-
Gracell Biotechnologies to Participate in Three Investor Conferences in May
-
Gracell Biotechnologies to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
-
Gracell Biotechnologies to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
-
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2021
-
Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2021
-
Gracell Biotechnologies to Participate in Three Investor Conferences in April
-
Gracell Biotechnologies to Participate in Three Investor Conferences in April
-
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies to Participate in Oppenheimer 32nd Annual Healthcare Conference
-
Gracell Biotechnologies to Participate in Oppenheimer 32nd Annual Healthcare Conference
-
Gracell Biotechnologies to Report Fourth Quarter & Full Year 2021 Financial Results on Monday, March 14, 2022
-
Gracell Biotechnologies to Report Fourth Quarter & Full Year 2021 Financial Results on Monday, March 14, 2022
-
Gracell Biotechnologies to Participate in Citi 2022 Virtual Immuno-Oncology Summit
-
Gracell Biotechnologies to Participate in Citi 2022 Virtual Immuno-Oncology Summit
-
Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference
-
Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference
-
Annual Changes to the Nasdaq Biotechnology Index
-
Gracell Biotechnologies to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
-
Gracell Biotechnologies to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
-
Gracell Biotechnologies Reports Third Quarter 2021 Unaudited Financial Results and Provides Corporate Update
-
Gracell Biotechnologies Reports Third Quarter 2021 Unaudited Financial Results and Provides Corporate Update
Back to GRCL Stock Lookup
